Category Archives: Recent Investment

SWAN is pleased to announce an investment in Vessl Prosthetics, which creates affordable, adaptive prosthetic sockets that automatically adjust to limb changes, offering bionic-level functionality and greater comfort for wearers.

Vessl has developed a new prosthetic socket designed specifically for amputees who have struggled to find a good fit with traditional sockets or who have felt that affordable options were not available to them. Vessl’s socket is the only socket that automatically adjusts as amputees’ legs change size. Custom panels maintain a consistent, clinician-set level of pressure on the leg even as the leg shrinks and swells. This socket is compatible with standard connectors, so prosthetists can easily integrate the Vessl socket with any shank and foot they choose. Vessl’s socket can be worn every day without pain or the need for prosthetic socks.

SWAN is pleased to announce an investment in AiM Medical Robotics, a company advancing neurosurgical precision and outcomes through real-time MRI-guided robotics.

AiM Medical Robotics is a neurosurgical robotics company that is working to bring high levels of precision, automation, and efficiency to the complex environment of neurosurgery. They are developing a portable MRI compatible surgical robot for use in the MRI Suite and the Operating Room. Their mission is to improve outcomes for patients undergoing neurosurgery for Functional brain disorders (Parkinson’s, Epilepsy, etc.) and cancer, while providing cost savings to hospitals by eliminating errors and reducing procedure time by up to 50%.

SWAN is pleased to announce an investment in AGED Diagnostics, which is using genomic innovation to develop the most accurate blood test for liver disease to help physicians keep patients in the monitoring program, reduce the financial burden for health insurers, and improve patient outcomes through early detection and intervention.

AGED tools can differentiate benign from advanced liver disease and simultaneously stage fibrosis (liver scarring). Their technology uses a targeted genomic sequencing assessment to measure the concentration of target biomarkers (genetic signatures) in circulation. The presence of biomarkers past a defined concentration indicates a diagnosis of liver disease (NASH) and/or fibrosis.